MedPath

Dry Run of the ScreenUrSelf Trial

Not Applicable
Completed
Conditions
HPV-Related Cervical Carcinoma
Cervical Intraepithelial Neoplasia
Human Papilloma Virus
Cervical Cancer
Interventions
Device: Evalyn Brush
Device: Colli-Pee Small Volumes
Registration Number
NCT05996796
Lead Sponsor
Universiteit Antwerpen
Brief Summary

The proposed study is the Dry Run preceding the ScreenUrSelf trial.

Detailed Description

The ScreenUrSelf trial will be embedded in the Flemish organized cervical cancer screening program. The goal of ScreenUrSelf is to reach women who are eligible but do not participate in cervical cancer screening, by offering two self-sampling methods (first-void urine and vaginal) in an opt-in and -out strategy (total of four interventions) to collect samples for primary high-risk (hr) Human Papillomavirus (HPV) testing, and if positive, reflex 1) cytology on a Pap smear (standard of care) and 2) methylation marker triage (index test). The two control arms include 1) no intervention; and 2) sending (recall) invitation letters to women, inviting them to make an appointment for a Pap smear (i.e., current practice within the organized cervical cancer screening program in Flanders).

The Dry Run which is the subject of this clinical trial will test the study materials and data flows developed for the interventional study arms (C, D, E and F) of the ScreenUrSelf trial. The primary outcome of the Dry Run is to check if the flow for data- and sample collection is ready for start of the ScreenUrSelf trial, and if optimizations are deemed necessary before start of the trial.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
38
Inclusion Criteria
  • Eligible for cervical cancer screening within the organized Population-based Screening Program in Flanders:

    • Female
    • Residing in Flanders, Belgium
    • No history of total hysterectomy
    • No (former) diagnosis of cervical or uterine cancer
    • 30 - 64 years old (birth year 1959 - 1992)
Exclusion Criteria
  • Being pregnant or 6 weeks postpartum (self-reported after receiving the study letter/package)
  • Participation during menstruation or within the 3 following days is a contraindication
  • Not able to understand the study materials and participation form (informed consent form)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Opt-in vaginal self-sampleEvalyn BrushWomen will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a vaginal self-sampling study package. The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.
Opt-out first-void urineColli-Pee Small VolumesWomen will receive a first-void urine self-sampling study package at home. The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.
Opt-in first-void urineColli-Pee Small VolumesWomen will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a first-void urine self-sampling study package. The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.
Opt-out vaginal self-sampleEvalyn BrushWomen will receive a vaginal self-sampling study package at home. The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.
Primary Outcome Measures
NameTimeMethod
HPV DNA using the Riatol qPCR HPV genotyping assayThrough study completion, an average of 1 year

HPV DNA concentration \[copies/µl DNA\] in self-samples from all study participants.

Secondary Outcome Measures
NameTimeMethod
Human DNA (Beta-globin) using the Riatol qPCR HPV genotyping assayThrough study completion, an average of 1 year

Human DNA concentration \[copies/µl DNA\] in self-samples from all study participants

PreferencesThrough study completion, an average of 1 year

Preferences and attitudes of women regarding self-sampling (measured using a questionnaire)

Trial Locations

Locations (1)

Universiteit Antwerpen

🇧🇪

Edegem, Antwerp, Belgium

© Copyright 2025. All Rights Reserved by MedPath